Enveric has already received expressions of interest in the PsyAI marks, which are positioned for potential use in AI-driven healthcare solutions, particularly in psychiatric medicine. The global AI market is projected to grow significantly, with healthcare applications expanding in diagnostics, treatment planning, and personalized medicine. Enveric aims to maximize the value of the PsyAI trademark through this RFP process while continuing to advance EB-003 for neuropsychiatric conditions. The company is headquartered in Naples, FL, with offices in Cambridge, MA, and Calgary, AB, Canada.
Key takeaways:
- Enveric Biosciences is soliciting Requests-For-Proposal (RFPs) for the license or sale of its PsyAI trademark portfolio, as it shifts focus to drug development.
- The PsyAI trademark was intended for use in data analytics and AI in medical research, but Enveric is now focusing on its lead compound, EB-003, for neuropsychiatric conditions.
- The global AI market is projected to reach $757 billion by 2025, with significant growth expected in AI-driven healthcare solutions, making the PsyAI mark a valuable asset.
- The RFP process for the PsyAI trademark portfolio is open until August 31, 2025, with a decision expected within three months thereafter.